advanced non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Yokohama City University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients This study will include patients with advanced non-small cell lung cancer (NSCLC), encompassing metastatic, relapsed, and locally advanced diseases. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and non-squamous cancers are considered eligible. Studies exclusively targeting large cell neuroendocrine carcinoma (LCNEC) will be excluded. Treatment The experimental regimens must contain immune checkpoint inhibitors (ICIs), including PD-1 inhibitors, PD-L1 inhibitors, or CTLA-4 inhibitors. LAG-3 inhibitors will be excluded as no phase III trials are available at the time of the search. The analysis will include ICI monotherapy, dual ICI combinations, and ICIs combined with cytotoxic therapies. Both first-line and subsequent lines of therapy will be eligible. The control regimens must consist of cytotoxic therapies, placebo, or best supportive care. Molecular targeted therapies and ICIs must not be included in the control regimen. Based on the treatment regimens, studies will be categorized into three groups: (1) platinum-doublet chemotherapy plus one PD-(L)1 inhibitor, (2) ICI monotherapy, and (3) regimens containing CTLA-4 inhibitors. Study design and reporting style This study will include phase III trials (or phase II/III trials) published as full research article.
Exclusion criteria
Exclusion criteria: Studies exclusively targeting large cell neuroendocrine carcinoma (LCNEC) will be excluded. Chemoradiotherapy and perioperative treatments, including adjuvant or neoadjuvant therapy, will be excluded. Abstracts and non-English publications will be excluded. Studies that do not provide hazard ratios (HRs) for subgroups based on sex and smoking history will also be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| rate of hazard ratio (RHR) of OS | — |
Countries
Japan
Contacts
Public ContactNobuyuki Horita
Yokohama City University Hospital Chemotherapy Center
Outcome results
None listed